Tag Archives: opko

BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry

MIAMI, June 22, 2021 /PRNewswire/ — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a COVID-19 testing program for U.S. based crew and guests who cruise with Royal Caribbean Group, helping provide a safe environment for travelers. Under the agreement, unvaccinated guests will be required to undergo rapid, point-of-care PCR COVID-19 prior to embarking. These guests will […]

Labs Preparing for Increase in POC, Home Testing Post-Pandemic

360Dx NEW YORK – COVID-19 has driven an uptick in healthcare delivery approaches like telemedicine and point-of-care, home, and direct-to-consumer testing, a shift that some observers believe could continue to accelerate even after the pandemic is over. Click here for full post on 360Dx website

Gestalt Diagnostics’ PathFlow Selected by BioReference Laboratories for Pathology Laboratory Business

SPOKANE, Wash., March 30, 2021 /PRNewswire/ — Gestalt Diagnostics today announced, that BioReference Laboratories Inc., an OPKO Health company, has selected their digital pathology solution, PathFlow®, to support its pathology business. PathFlow is an enterprise software platform specifically designed to bring the benefits of digital workflow to pathologists and pathology laboratories. Under the agreement, Gestalt is partnering […]

OPKO Health’s BioReference Laboratories Team-up with the National Basketball Association and National Hockey League to Provide Players and Staff with COVID-19 Testing

BioReference executes COVID-19 testing program for NBA and NHL for 2020-21 seasons, as well as U.S. Women’s and Men’s National Soccer Teams, Winter X Games and NBA G League ELMWOOD PARK, N.J., January 26, 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced COVID-19 testing agreements for players and officials, as well […]

OPKO Health’s BioReference Laboratories Introduces Scarlet Health™, an In-Home Diagnostic Service to Expand Digital Health Access

Scarlet brings diagnostic service to patients’ homes, offices and other preferred locations, delivering an on-demand, safe and convenient diagnostic experience for patients and healthcare providers ELMWOOD PARK, N.J., January 13, 2021 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today introduced Scarlet Health™, an in-home, fully integrated digital platform providing access to on-demand diagnostic […]

OPKO Health’s BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide

Nearly 210,000 New York City students, teachers, principals and staff were tested by BioReference with a positivity rate of 0.47% ELMWOOD PARK, N.J., (January 4, 2021) – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the results of COVID-19 molecular PCR tests for public schools throughout New York City’s boroughs, with a positivity rate of […]

Buffalo Bills and OPKO Health’s BioReference Laboratories Initiate the First Large Scale, Mandatory COVID-19 Fan Testing Program

The Bills leverage testing capabilities from NFL testing provider, BioReference, to initiate fan testing program ORCHARD PARK, N.Y., December 31, 2020 – Buffalo Bills, 2020 AFC East Division Champions, and BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced they will be performing fan testing for the AFC Divisional Wild Card playoff game at […]

OPKO Health’s BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test

New offering identifies COVID-19 and Influenza infections with a single sample ELMWOOD PARK, N.J., October 20, 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), is now accepting specimens for a new multiplex COVID-19 and influenza test for use by healthcare providers, clinics and health systems throughout the United States, to aid in the […]

OPKO Health’s BioReference Laboratories Launches COVID-19 Testing Program for New York City Schools

Through New York City, BioReference will be testing students, teachers and staff in nearly 1,000 NYC public schools ELMWOOD PARK, N.J., October 9, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the beginning of its COVID-19 testing program for New York City schools throughout the 2020-2021 school year to help ensure a safer school […]

OPKO Health’s BioReference Laboratories Announces New York City Schools COVID-19 Testing Program

The COVID-19 testing program will test principals, teachers and staff in preparation for a safer back-to-school environment ELMWOOD PARK, N.J., September 2, 2020 — BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today began testing New York City principals, teachers and other staff for COVID-19, across the five boroughs, in preparation for a safer back-to-school environment. Through a […]